Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACHL NASDAQ:AVRO NYSE:IKT NYSE:PLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHLAchilles Therapeutics$1.48$1.48$0.63▼$1.51$60.83M1.25735,654 shsN/AAVROAVROBIO$9.98$0.88▼$1.65$62.85M1.23269,831 shs206,800 shsIKTInhibikase Therapeutics$1.92+1.9%$1.90$1.12▼$4.20$141.62M0.92279,744 shs35,177 shsPLXProtalix BioTherapeutics$1.55+1.6%$1.53$0.82▼$3.10$122.99M-0.23601,872 shs579,693 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHLAchilles Therapeutics0.00%0.00%0.00%0.00%+77.20%AVROAVROBIO0.00%0.00%0.00%0.00%0.00%IKTInhibikase Therapeutics+2.17%-3.09%+13.25%-4.08%+25.33%PLXProtalix BioTherapeutics+4.83%+7.04%+8.57%-42.21%+38.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACHLAchilles TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAVROAVROBION/AN/AN/AN/AN/AN/AN/AN/AIKTInhibikase Therapeutics1.268 of 5 stars3.31.00.00.00.00.00.6PLXProtalix BioTherapeutics2.8393 of 5 stars3.53.00.00.01.80.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHLAchilles Therapeutics 0.00N/AN/AN/AAVROAVROBIO 0.00N/AN/AN/AIKTInhibikase Therapeutics 2.50Moderate Buy$6.50239.43% UpsidePLXProtalix BioTherapeutics 3.00Buy$15.00870.87% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHLAchilles TherapeuticsN/AN/AN/AN/A$3.49 per shareN/AAVROAVROBION/AN/AN/AN/A$2.13 per shareN/AIKTInhibikase TherapeuticsN/AN/AN/AN/A$1.78 per shareN/APLXProtalix BioTherapeutics$59.76M2.06$0.09 per share17.80$0.47 per share3.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHLAchilles Therapeutics-$69.67M-$1.65N/AN/AN/AN/A-54.45%-47.68%8/12/2025 (Estimated)AVROAVROBIO$12.16M$0.692.03N/AN/AN/A-50.52%-47.13%N/AIKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/APLXProtalix BioTherapeutics$8.31M$0.04N/A4.98N/A-21.03%-30.89%-11.74%N/ALatest AVRO, IKT, PLX, and ACHL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1PLXProtalix BioTherapeuticsN/A-$0.05N/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACHLAchilles TherapeuticsN/AN/AN/AN/AN/AAVROAVROBION/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/APLXProtalix BioTherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHLAchilles TherapeuticsN/A6.046.04AVROAVROBION/A26.1726.17IKTInhibikase TherapeuticsN/A0.850.85PLXProtalix BioTherapeuticsN/A1.981.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHLAchilles Therapeutics56.38%AVROAVROBIO62.63%IKTInhibikase Therapeutics3.81%PLXProtalix BioTherapeutics16.53%Insider OwnershipCompanyInsider OwnershipACHLAchilles Therapeutics5.38%AVROAVROBIO9.20%IKTInhibikase Therapeutics7.30%PLXProtalix BioTherapeutics6.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACHLAchilles Therapeutics25041.10 million38.89 millionNot OptionableAVROAVROBIO1344.89 million40.76 millionOptionableIKTInhibikase Therapeutics674.34 million66.18 millionNot OptionablePLXProtalix BioTherapeutics20079.61 million69.00 millionOptionableAVRO, IKT, PLX, and ACHL HeadlinesRecent News About These CompaniesProtalix BioTherapeutics Names Gilad Mamlok Chief Financial OfficerJuly 21 at 9:55 AM | marketwatch.comProtalix BioTherapeutics Names SVP and CFOJuly 21 at 9:55 AM | contractpharma.comCProtalix Biotherapeutics Inc.: Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial OfficerJuly 21 at 9:55 AM | finanznachrichten.deProtalix BioTherapeutics welcomes new finance chiefJuly 21 at 9:09 AM | proactiveinvestors.comPLX | Protalix BioTherapeutics Inc. Annual Cash Flow Statement ...July 10, 2025 | marketwatch.comProtalix BioTherapeutics (NYSE:PLX) Shares Up 3.4% - Still a Buy?July 10, 2025 | marketbeat.comProtalix BioTherapeutics joins Russell 3000 and 2000 indexes following annual reconstitutionJune 30, 2025 | proactiveinvestors.comProtalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYCMay 14, 2025 | finance.yahoo.comPLX: First Quarter ResultsMay 13, 2025 | msn.comEarnings call transcript: Protalix Q1 2025 results miss forecasts, stock plungesMay 10, 2025 | uk.investing.comProtalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2025 Earnings Call TranscriptMay 10, 2025 | insidermonkey.comProtalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business ResultsMay 10, 2025 | finanznachrichten.deProtalix BioTherapeutics Q1 Earnings PreviewMay 10, 2025 | msn.com1PLX : Uncovering Potential: Protalix BioTherapeutics's Earnings PreviewMay 10, 2025 | benzinga.comProtalix BioTherapeutics, Inc. (PLX) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comProtalix eyes Phase II gout trial later this year following solid Q1 revenue growthMay 9, 2025 | proactiveinvestors.comProtalix BioTherapeutics Reports First Quarter 2025 Financial and Business ResultsMay 9, 2025 | prnewswire.comProtalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025May 6, 2025 | seekingalpha.comWhy Protalix BioTherapeutics, Inc.’s (PLX) Stock Is Up 8.71%April 15, 2025 | aaii.comAProtalix BioTherapeutics Is A Strong Buy With Increasing Revenues And A Promising PipelineApril 10, 2025 | seekingalpha.comProtalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025March 24, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVRO, IKT, PLX, and ACHL Company DescriptionsAchilles Therapeutics NASDAQ:ACHLAchilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.AVROBIO NASDAQ:AVROAVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Inhibikase Therapeutics NYSE:IKT$1.92 +0.04 (+1.86%) As of 03:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.Protalix BioTherapeutics NYSE:PLX$1.54 +0.03 (+1.64%) As of 03:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rigetti Soars 30% on Latest Quantum Leap: What It Means Long-Term Domino’s Delivers Another Discounted Entry for Income Investors Palantir Bulls and Bears Set for an August Showdown 3 Reasons Palo Alto Networks Is Becoming a Wall Street Favorite Vertical Aerospace Stock Trades at Discount After VX4 Milestone GameStop: Clarity Brings Renewed Confusion for Meme Stock Analysts Are Backing Qualcomm: Is a Breakout Coming? TSLA Earnings Week: Can Tesla Break Through $350? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.